Cargando…
Biologics in the management of psoriasis
Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha an...
Autores principales: | Bahner, Jennifer D, Cao, Lauren Y, Korman, Neil J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047928/ https://www.ncbi.nlm.nih.gov/pubmed/21436974 |
Ejemplares similares
-
Management of psoriasis as a systemic disease: what is the evidence?
por: Korman, N.J.
Publicado: (2019) -
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023) -
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009) -
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
por: Al-Janabi, A, et al.
Publicado: (2022) -
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)